New! The AMMF Cholangiocarcinoma Scholarship
AMMF is delighted to announce The AMMF Cholangiocarcinoma Scholarship, a three-year PhD award. The first of these three-year AMMF funded PhD studentships is specifically to investigate the role of mutations in bile duct cancer (cholangiocarcinoma). The successful PhD student will be based at The Boulter Lab, located in the MRC Human Genetics Unit at the University of Edinburgh. The Boulter lab is r...
Read MoreAMMF launches ‘Our CC Family – Your Story’
For the past five years during each February, Cholangiocarcinoma Awareness Month, AMMF has run a daily Guest Post feature on Facebook, which has proved to be extremely important to our supporters. Over those years, the response to this feature has grown enormously and, because of the limitation of the number of days in the month, we know that ...
Read MoreNow Published! The MDT: Cholangiocarcinoma Patients’ Observations
“The multidisciplinary team meeting in the UK from the patients’ perspective: comments and observations from cholangiocarcinoma patients and their families” The thoughts of cholangiocarcinoma patients and their families on what they understood an MDT meeting to be, and their experiences around such meetings, were the basis of a paper by AMMF CEO Helen Morement, which has now been publis...
Read MoreThe Cancer52 CNS Report
Through their work, Clinical Nurse Specialists (CNS) can bring invaluable support and humanity to the treatment and care of their patients. To demonstrate the importance of their work, and how it can improve the quality of life for patients diagnosed with the rare and less common cancers, Cancer52¹ have produced a report: “Clinical Nurse Specialists working with people with rare and less common...
Read MoreAMMF joins European Reference Network (Rare-Liver)
AMMF is now a representative and advocate for cholangiocarcinoma patients within ERN-RARE-LIVER, the rare hepatic disease section of the European Research Networks. ERN RARE-LIVER is looking to connect expert centres across Europe, including the UK, to improve access to diagnosis, treatment and high quality care for patients with rare liver diseases. To find out more about the work of the ERNs click...
Read MoreProfessor Narong’s fight against cholangiocarcinoma hits the headlines
The work of Professor Narong Khuntikeo, who was a keynote speaker at AMMF’s cholangiocarcinoma conference earlier this year, has been hitting headlines in the health sections of the British press over the last few days. In the Isaan region, which has the world's highest incidence of cholangiocarcinoma¹, millions of Thais regularly eat a dish made from fresh water river fish. This fish dish, koi ...
Read MoreNew insights to the mechanisms driving cholangiocarcinoma
An enormous unmet clinical need exists for novel therapies in cholangiocarcinoma (cancer of the bile ducts). This disease has a poor prognosis; patients often present too late for the only curative procedure - surgical resection, and investigations to obtain tissue for diagnostic confirmation are invasive and often inconclusive. There is currently no serum biomarker of the disease, which would aid early dia...
Read MoreAMMF’s Conference 2017 – Presentations
Here we share some of the presentations from AMMF's Cholangiocarcinoma Conference, held on 11th May 2017. (Please note, we are unable to share the research presentations as much of the work we heard about is as yet unpublished and, for that reason, must remain confidential.) To download Dr Shahid Khan's presentation, “Cholangiocarcinoma - An overview”, click here ...
Read MoreThe BILCAP study results …
With the kind permission of Professor John Primrose, AMMF is now able to share the BILCAP presentation slides from the ASCO 2017 meeting. These slides show details of the BILCAP study and its outcome. The study looked at whether or not giving cholangiocarcinoma patients Capecitabine chemotherapy following resection would be beneficial. The outcome is positive - Capecitabine will now be recommended t...
Read MoreBILCAP results show chemo improves survival
AMMF welcomes the encouraging results announced today by Cancer Research UK following the BILCAP trial into the use of the chemotherapy drug Capecitabine (Xeloda) for bile duct cancer (cholangiocarcinoma) patients following surgery. The three year survival improved by almost a quarter (23 per cent) in patients who were given Capecitabine, and the average survival was increased to 53 months from 36 months...
Read More
